Product How it works Pricing Blog FAQ About Contact
Iovance Biotherapeutics

Iovance Biotherapeutics (NASDAQ: IOVA) revenue

Iovance Biotherapeutics reported revenue of $263.5m for fiscal 2025, 60.6% more than in fiscal 2024 ($164.1m).

Iovance Biotherapeutics has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.

Revenue, in millions of US dollars0.020160.020170.020181.22023164.12024263.52025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$263.5m+60.6%−$403.4m−153.1%
2024$164.1m+13,699.0%−$395.3m−240.9%
2023$1.2m—−$460.6m−38,735.0%
2018$0.0m—−$128.3m—
2017$0.0m—−$92.9m—
2016$0.0m—−$53.6m—

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Iovance Biotherapeutics revenue compared with its sector

By revenue for its latest fiscal year, Iovance Biotherapeutics ranks 230th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Iovance Biotherapeutics, 60.6%.

RankCompanyRevenueRevenue growth
228thViemed Healthcare$270.3m20.5%
229thLigand Pharmaceuticals$268.1m60.4%
230thIovance Biotherapeutics$263.5m60.6%
231stArvinas$262.6m−0.3%
232ndSchrodinger$255.9m23.3%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Iovance Biotherapeutics

How much revenue did Iovance Biotherapeutics make in fiscal 2025?
Iovance Biotherapeutics reported revenue of $263.5m for fiscal 2025, compared with $164.1m in fiscal 2024.
What was the best year for revenue at Iovance Biotherapeutics?
Of its last 6 fiscal years, fiscal 2025, with $263.5m.
Where does Iovance Biotherapeutics rank in its sector by revenue?
It ranks 230th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Iovance Biotherapeutics come from?
From the annual report (Form 10-K) that Iovance Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Iovance Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2018 · 2017 · 2016. More on Iovance Biotherapeutics: the Iovance Biotherapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.